Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - thelancet.com
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …
被引用次数：498 相关文章

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - Elsevier
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - 2016 - pubmed.ncbi.nlm.nih.gov
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

SUMMIT Investigators - The Lancet, 2016 - portal.findresearcher.sdu.dk
Background: Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - hero.epa.gov
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

SUMMIT Investigators - The Lancet, 2016 - research.ed.ac.uk
Background: Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - 2016 - dspace.vnmu.edu.ua
Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease.
Treatments for airflow limitation might improve survival and both respiratory and …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - thelancet.com
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - infona.pl
Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease.
Treatments for airflow limitation might improve survival and both respiratory and …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook… - Lancet (London …, 2016 - europepmc.org
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …